Kolon TissueGene, Inc. (KOSDAQ:950160)

Market Cap	8.71T +106.6%
Revenue (ttm)	5.16B +1.7%
Net Income	-192.59B
EPS	-2,343.80
Shares Out	84.15M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	432,517
Average Volume	557,970
Open	103,600
Previous Close	103,500
Day's Range	98,000 - 103,600
52-Week Range	31,250 - 130,700
Beta	-0.54
RSI	47.64
Earnings Date	n/a

About Kolon TissueGene

Kolon TissueGene, Inc. develops cell therapies for orthopedic diseases and other unmet medical needs. The company’s lead product is the TG-C that has completed Phase II trials to treat osteoarthritis, as well as rheumatoid arthritis, meniscus, and spinal discs. It is also developing cell therapies for musculoskeletal system disorders, as well as vet medicine. Kolon TissueGene, Inc. was formerly known as TissueGene, Inc. and changed its name to Kolon TissueGene, Inc. in March 2018. The company was founded in 1999 and is headquartered in Rockvill...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 29
• Stock Exchange: KOSDAQ
• Ticker Symbol: 950160

Financial Performance

In 2025, Kolon TissueGene's revenue was 5.16 billion, an increase of 1.68% compared to the previous year's 5.07 billion. Losses were -192.59 billion, 469.8% more than in 2024.